Live
- SC restores evidence-tampering case against former Kerala Minister Antony Raju in 'underwear' matter
- Apple’s $100 Million Bid to Reverse iPhone 16 Ban in Indonesia
- 'When BCCI want things to happen, they get their way': Finch on IPL auction dates
- Revolutionizing Customer Service: Enhancing Customer Experience through OneConnect Project and SAP Service Cloud
- Delhi govt to implement work from home for 50 pc govt staff amid severe air pollution
- Annual addition to green energy capacity likely to surpass 35 GW: Report
- Seeking to complete 1st nuclear power plant as scheduled: Egyptian PM Madbouly
- Priyanka Chopra shares heartwarming moment of Malti enjoying Autumn
- "We play with passion and pride', says captain Durga Rao after India pulls out of Blind T20 World Cup
- Rural India’s women entrepreneurs: Stories of grit and success
DRL arm launches anti-psoriasis spray
Promius Pharma LLC, the US subsidiary of city-based pharmaceutical major Dr Reddy’s Laboratories Limited (DRL), has launched Sernivo (betamethasone dipropionate) spray 0.05 per cent in the US.
Hyderabad: Promius Pharma LLC, the US subsidiary of city-based pharmaceutical major Dr Reddy’s Laboratories Limited (DRL), has launched Sernivo (betamethasone dipropionate) spray 0.05 per cent in the US.
Sernivo spray, a prescription-topical steroid approved by the US Food and Drug Administration (US FDA) in February 2016, is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older.
“We are proud to bring Sernivo spray to patients across the US,” said Raghav Chari, Executive Vice-President (proprietary products group) at Dr Reddy’s. “This is another significant milestone for Promius Pharma.
Plaque psoriasis can be a frustrating condition for patients and physicians alike. For patients, it is not only itchy and painful, but depending on where on the body it occurs, it can be embarrassing for them and decrease their quality of life
As an emerging leader in the dermatology space, we are committed to developing innovative treatment options,” he said in a statement on Wednesday.
“Plaque psoriasis can be a frustrating condition for patients and physicians alike. For patients, it is not only itchy and painful, but depending on where on the body it occurs, it can be embarrassing for them and decrease their quality of life,” said Leon H Kircik, MD (clinical associate professor of dermatology) at Indiana University School of Medicine.
Dr Reddy’s claims that the anti-psoriasis spray achieved treatment success of 42.7 per cent and 34.5 per cent during Studies-I and Studies-II, respectively, on Day-29 of clinical trials. Dr Reddy’s scrip ended the trade at Rs 3,182.95 on the BSE on Wednesday, down 0.05 per cent, over the previous close of Rs 3,184.40 apiece.
